New insights into mechanisms of hypertension

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 2, 2012, Pages 119-121

  Touyz, Rhian M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; ENDOTHELIN 1; MINERALOCORTICOID RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C; POTASSIUM CHANNEL; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN;

APOPTOSIS; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE FLUCTUATION; CALCIFICATION; CELL FUNCTION; CELL GROWTH; DIABETES MELLITUS; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; ERECTILE DYSFUNCTION; HEART FAILURE; HEREDITY; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; IMMUNE SYSTEM; KIDNEY; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; OBESITY; PATHOPHYSIOLOGY; PHENOTYPE; PREECLAMPSIA; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; STROKE; T LYMPHOCYTE; VASCULAR DISEASE;

ERECTILE DYSFUNCTION; FEMALE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; PRE-ECLAMPSIA; PREGNANCY; SIGNAL TRANSDUCTION; SODIUM;

EID: 84857060117     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e328350a50f     Document Type: Review

References (17)

1. Kakar P, Lip GY. Towards understanding the aetiology and pathophysiology of human hypertension: Where are we now? J Hum Hypertens 2006; 20:833-836. (Pubitemid 44614064)
2. Kannel WB. Hypertension: Reflections on risks and prognostication. Med Clin North Am 2009; 93:541-558.
3. Mittal BV, Singh AK. Hypertension in the developing world: Challenges and opportunities. Am J Kidney Dis 2010; 55:590-598.
4. Chobanian AV. Impact of nonadherence to antihypertensive therapy. Circulation 2009; 120:1558-1560.
5. Chobanian AV. Mixed messages on blood pressure goals. Hypertension 2011; 57:1039-1040.
6. Zubcevic J, Waki H, Raizada MK, Paton JF. Autonomic-immune-vascular interaction: An emerging concept for neurogenic hypertension. Hypertension 2011; 57:1026-1033.
7. Muller DN, Kvakan H, Luft FC. Immune-related effects in hypertension and target-organ damage. Curr Opin Nephrol Hypertens 2011; 20:113-117.
8. Savoia C, Burger D, Nishigaki N, et al. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med 2011; 13:e11.
9. Lurbe E, Torró MI. Early vascular phenotypes in the genesis of hypertension. Pediatr Nephrol 2010; 25:763-767.
10. Nilsson PM. Early vascular aging (EVA): Consequences and prevention. Vasc Health Risk Manag 2008; 4:547-552. (Pubitemid 352042403)
11. Kahle KT, Rinehart J, Giebisch G, et al. A novel protein kinase signaling pathway essential for blood pressure regulation in humans. Trends Endocrinol Metab 2008; 19:91-95. (Pubitemid 351447290)
12. Briones AM, Touyz RM. Oxidative stress and hypertension: Current concepts. Curr Hypertens Rep 2010; 12:135-142.
13. Fisher SA. Vascular smooth muscle phenotypic diversity and function. Physiol Genomics 2010; 42A:169-187.
14. Higuchi S, Ohtsu H, Suzuki H, et al. Angiotensin II signal transduction through the AT1 receptor: Novel insights into mechanisms and pathophysiology. Clin Sci (Lond) 2007; 112:417-428. (Pubitemid 46587457)
15. Bastin G, Heximer SP. Intracellular regulation of heterotrimeric G-protein signaling modulates vascular smooth muscle cell contraction. Arch Biochem Biophys 2011; 510:182-189.
16. Rautureau Y, Paradis P, Schiffrin EL. Cross-talk between aldosterone and angiotensin signaling in vascular smooth muscle cells. Steroids 2011; 76:834-839.
17. Choi M, Scholl UI, Yue P, et al. KR channel mutations in adrenal aldosteroneproducing adenomas and hereditary hypertension. Science 2011; 331:768-772.